FGP
CPRX

Freestone Grove Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Freestone Grove Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,568
Closed -$1.75M – 1086
2026
Q1 		$1.75M Buy
70,568
+39,654
+128% +$945K 0.01% 391
2025
Q4 		$722K Sell
30,914
-29,823
-49% -$664K 0.01% 511
2025
Q3 		$1.2M Buy
+60,737
New +$1.25M 0.01% 415

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Freestone Grove Partners's CPRX Position: Q2 2026 in Review

Freestone Grove Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 70,568 shares — an estimated $1.75M sold.

Freestone Grove Partners first reported a position in CPRX in Q3 2025 and held it in 3 quarters. The position peaked at $1.75M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Freestone Grove Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 70,568 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.75M.
  • Freestone Grove Partners first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 3 quarters.
  • Freestone Grove Partners's Catalyst Pharmaceutical position peaked at $1.75M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.